A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
accepted:
18
07
2021
pubmed:
12
8
2021
medline:
28
10
2021
entrez:
11
8
2021
Statut:
ppublish
Résumé
To date, the economic burden and patient-reported outcomes associated with carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) remain largely unknown. The objective of this study was to perform a systematic review of economic and quality-of-life (QOL) studies related to the treatment of CS. Articles included in the review were extracted from PubMed, Embase, and the Cochrane Library. Studies had to be in English and published between 1 January 2000 and 2 July 2020. Other study eligibility criteria included patients with NET with CS receiving treatment for CS, study outcomes of cost or QOL, and clinical trials or population-based studies using claims or other secondary databases. The interventions included somatostatin analogs, telotristat ethyl, or other treatment for CS. To evaluate the quality and bias of the included studies, the 24-item CHEERS and 10-item Gill and Feinstein checklists were used. We report a narrative synthesis of the findings from the selected studies. A total of 12 economic and 12 QOL studies met the inclusion criteria and were included for review. Patients with uncontrolled CS symptoms had 23-92% higher costs than those with controlled CS; mostly, ambulatory/outpatient services were the primary drivers of the costs. The use of telotristat ethyl may be cost effective if the societal willingness to pay is as high as $US150,000 per quality-adjusted life-year in the USA. Of the 12 QOL papers, only three case-control studies assessed QOL at baseline and more than two follow-up time points. Seven studies evaluated QOL at two or more time points but lacked a control group, obscuring direct intervention effects on patients' well-being. We observed wide variations in the reviewed studies evaluating the economic burden and patient-reported outcomes, in terms of cost and QOL, of patients with CS. Although QOL is consistently impaired and costs are consistently increased by CS, the numbers of both cost and QOL studies among this patient population remain sparse, and many of the existing studies indicated an important need for quality improvement.
Sections du résumé
BACKGROUND
To date, the economic burden and patient-reported outcomes associated with carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) remain largely unknown.
OBJECTIVES
The objective of this study was to perform a systematic review of economic and quality-of-life (QOL) studies related to the treatment of CS.
METHODS
Articles included in the review were extracted from PubMed, Embase, and the Cochrane Library. Studies had to be in English and published between 1 January 2000 and 2 July 2020. Other study eligibility criteria included patients with NET with CS receiving treatment for CS, study outcomes of cost or QOL, and clinical trials or population-based studies using claims or other secondary databases. The interventions included somatostatin analogs, telotristat ethyl, or other treatment for CS. To evaluate the quality and bias of the included studies, the 24-item CHEERS and 10-item Gill and Feinstein checklists were used. We report a narrative synthesis of the findings from the selected studies.
RESULTS
A total of 12 economic and 12 QOL studies met the inclusion criteria and were included for review. Patients with uncontrolled CS symptoms had 23-92% higher costs than those with controlled CS; mostly, ambulatory/outpatient services were the primary drivers of the costs. The use of telotristat ethyl may be cost effective if the societal willingness to pay is as high as $US150,000 per quality-adjusted life-year in the USA. Of the 12 QOL papers, only three case-control studies assessed QOL at baseline and more than two follow-up time points. Seven studies evaluated QOL at two or more time points but lacked a control group, obscuring direct intervention effects on patients' well-being.
CONCLUSIONS
We observed wide variations in the reviewed studies evaluating the economic burden and patient-reported outcomes, in terms of cost and QOL, of patients with CS. Although QOL is consistently impaired and costs are consistently increased by CS, the numbers of both cost and QOL studies among this patient population remain sparse, and many of the existing studies indicated an important need for quality improvement.
Identifiants
pubmed: 34378163
doi: 10.1007/s40273-021-01071-0
pii: 10.1007/s40273-021-01071-0
pmc: PMC9109155
mid: NIHMS1802257
doi:
Types de publication
Research Support, N.I.H., Extramural
Systematic Review
Langues
eng
Pagination
1271-1297Subventions
Organisme : NCI NIH HHS
ID : R01 CA225647
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Dig Liver Dis. 2016 May;48(5):552-558
pubmed: 26917486
JAMA. 1994 Aug 24-31;272(8):619-26
pubmed: 7726894
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Lancet Oncol. 2017 Apr;18(4):525-534
pubmed: 28238592
Clin Ther. 2017 Dec;39(12):2338-2344
pubmed: 29175096
Scand J Gastroenterol. 2018 Dec;53(12):1509-1518
pubmed: 30449217
Endocr Pract. 2016 Sep;22(9):1068-80
pubmed: 27214300
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175
Oncologist. 2017 Dec;22(12):1451-1462
pubmed: 28642335
Oncology. 2019;96(6):273-289
pubmed: 31018209
J Med Econ. 2017 Sep;20(9):945-951
pubmed: 28562131
Pharmacoeconomics. 2020 Jun;38(6):607-618
pubmed: 32157590
Cancer. 2000 Feb 15;88(4):770-6
pubmed: 10679645
Future Oncol. 2018 Oct;14(23):2361-2370
pubmed: 30095284
J R Coll Gen Pract. 1985 Apr;35(273):185-8
pubmed: 3989783
Clin Ther. 2016 Apr;38(4):759-68
pubmed: 27041406
BMC Cancer. 2019 Mar 28;19(1):274
pubmed: 30922252
Expert Rev Pharmacoecon Outcomes Res. 2020 Oct;20(5):507-511
pubmed: 31448649
World J Gastroenterol. 2019 Dec 21;25(47):6857-6865
pubmed: 31885426
Medicine (Baltimore). 2018 Nov;97(47):e13390
pubmed: 30461659
Pancreas. 2012 Apr;41(3):461-6
pubmed: 22422138
Pancreas. 2019 Oct;48(9):1126-1135
pubmed: 31593022
Patient Relat Outcome Meas. 2019 Oct 29;10:335-343
pubmed: 31754316
Health Qual Life Outcomes. 2018 Dec 11;16(1):228
pubmed: 30537955
Clin Ther. 2017 Nov;39(11):2158-2168
pubmed: 29074312
Qual Life Res. 2019 Oct;28(10):2641-2650
pubmed: 31187410
Neuroendocrinology. 2004;80(4):244-51
pubmed: 15627802
World J Gastroenterol. 2016 Feb 14;22(6):2118-25
pubmed: 26877616
Endocr Relat Cancer. 2012 Sep 14;19(5):657-66
pubmed: 22807497
J Med Econ. 2018 Feb;21(2):182-188
pubmed: 28959913
J Patient Rep Outcomes. 2019 Oct 26;3(1):64
pubmed: 31655936
Br J Cancer. 2013 Feb 5;108(2):301-10
pubmed: 23322194
J Clin Oncol. 2017 Jan;35(1):14-23
pubmed: 27918724
Clin Ther. 2018 Dec;40(12):2006-2020.e2
pubmed: 30477789